In October 22, the FDA granted accelerated approval to teclistamab-cqvy for patients with relapsed/refractory multiple myeloma.
FDA Grants Accelerated Approval to Teclistamab-cqyv in Relapsed/Refractory Multiple Myeloma
Based on results from the phase 1/2 MajesTec-1 trial, the FDA has granted accelerated approval to teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.
Joseph Mikhael, MD, Discusses the FDA’s Approval of Teclistimab-cqyv in Relapsed/Refractory Multiple Myeloma
Teclistimab and similar bispecifics can have a prolific impact on patients with heavily relapsed multiple myeloma in the short term and possibly in earlier relapses in the long term, according to Joseph Mikhael, MD.
2 Clarke Drive Cranbury, NJ 08512